Evidence map›Paper›PMID 26246051›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2015

Zerumbone, a ginger sesquiterpene, induces apoptosis and autophagy in human hormone-refractory prostate cancers through tubulin binding and crosstalk between endoplasmic reticulum stress and mitochondrial insult.

Mei-Ling Chan, Jui-Wei Liang, Lih-Ching Hsu, Wei-Ling Chang, Shoei-Sheng Lee, Jih-Hwa Guh

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
6.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Effects of Ginger (Biomolecules · 2024
    Review
  3. Article
  4. Anticancer bioactivity of zerumbone on pediatric rhabdomyosarcoma cells.Journal of cancer research and clinical oncology · 2023
    Article
  5. Review
  6. Natural Products Targeting the Mitochondria in Cancers.Molecules (Basel, Switzerland) · 2020
    Review
  7. Review
  8. A Tale of Two States: Normal and Transformed, With and Without Rigidity Sensing.Annual review of cell and developmental biology · 2019
    Review
  9. Review
  10. Article
  11. Potential of Zerumbone as an Anti-Cancer Agent.Molecules (Basel, Switzerland) · 2019
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. The Natural Occurring Compounds Targeting Endoplasmic Reticulum Stress.Evidence-based complementary and alternative medicine : eCAM · 2016
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Mei-Ling ChanSchool of Pharmacy, National Taiwan University, No.33, Linsen S. Rd., Taipei, 100, Taiwan.
Jui-Wei LiangSchool of Pharmacy, National Taiwan University, No.33, Linsen S. Rd., Taipei, 100, Taiwan.
Lih-Ching HsuSchool of Pharmacy, National Taiwan University, No.33, Linsen S. Rd., Taipei, 100, Taiwan.
Wei-Ling ChangDivision of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, 43210, USA.
Shoei-Sheng LeeSchool of Pharmacy, National Taiwan University, No.33, Linsen S. Rd., Taipei, 100, Taiwan. shoeilee@ntu.edu.tw.
Jih-Hwa GuhSchool of Pharmacy, National Taiwan University, No.33, Linsen S. Rd., Taipei, 100, Taiwan. jhguh@ntu.edu.tw.
National Taiwan University · TWThe Ohio State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zerumbone, a natural monocyclic sesquiterpene, is the main component of the tropical plant Zingiber zerumbet Smith. Zerumbone induced antiproliferative and apoptotic effects against PC-3 and DU-145, two human hormone-refractory prostate cancer (HRPC) cell lines. Zerumbone inhibited microtubule assembly and induced an increase of MPM-2 expression (specific recognition of mitotic proteins). It also caused an increase of phosphorylation of Bcl-2 and Bcl-xL, two key events in tubulin-binding effect, indicating tubulin-binding capability and mitotic arrest to zerumbone action. Furthermore, zerumbone induced several cellular effects distinct from tubulin-binding properties. First, zerumbone significantly increased, while paclitaxel (as a tubulin-binding control) decreased, Mcl-1 protein expression. Second, paclitaxel but not zerumbone induced Cdk1 activity. Third, zerumbone other than paclitaxel induced Cdc25C downregulation. The data suggest that, in addition to targeting tubulin/microtubule, zerumbone may act on other targets for signaling transduction. Zerumbone induced mitochondrial damage and endoplasmic reticulum (ER) stress as evidenced by the loss of mitochondrial membrane potential and upregulation of GRP-78 and CHOP/GADD153 expression. Zerumbone induced an increase of intracellular Ca(2+) levels, a crosstalk marker between ER stress and mitochondrial insult, associated with the formation of active calpain I fragment. It induced apoptosis through a caspase-dependent way and caused autophagy as evidenced by dramatic LC3-II formation. In summary, the data suggest that zerumbone is a multiple targeting compound that inhibits tubulin assembly and induces a crosstalk between ER stress and mitochondrial insult, leading to apoptosis and autophagy in HRPCs.

Indexed as

ApoptosisApoptosis Regulatory ProteinsAutophagyCalciumCell CycleCell Cycle ProteinsCell Line, TumorEndoplasmic Reticulum StressHumansMaleMembrane Potential, MitochondrialProstatic Neoplasms, Castration-ResistantSesquiterpenesTubulinZingiber officinaleApoptosis Regulatory ProteinsCalciumCell Cycle ProteinsSesquiterpenesTubulinzerumboneAutophagyER stressHormone-refractory prostate cancersMitochondriaTubulin

Identifiers

PMID26246051
OpenAlexW1068482264

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.